

# Caroline Houillier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8584932/publications.pdf>

Version: 2024-02-01

28  
papers

937  
citations

567281

15  
h-index

501196

28  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1107  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life experience of the French Network. Bone Marrow Transplantation, 2022, 57, 966-974.	2.4	12
2	Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study. Hematological Oncology, 2022, 40, 976-986.	1.7	2
3	Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study. Journal of Clinical Oncology, 2022, 40, 3692-3698.	1.6	31
4	Clinical features and outcome of patients with primary central nervous system lymphoma admitted to the intensive care unit: a French national expert center experience. Journal of Neurology, 2021, 268, 2141-2150.	3.6	4
5	Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study. American Journal of Hematology, 2021, 96, 823-833.	4.1	18
6	Primary Central Nervous System Lymphoma in Elderly Patients: Management and Perspectives. Cancers, 2021, 13, 3479.	3.7	6
7	Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up. Current Opinion in Oncology, 2021, 33, 420-431.	2.4	8
8	Management and outcome of primary CNS lymphoma in the modern era. Neurology, 2020, 94, e1027-e1039.	1.1	125
9	Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood, 2020, 135, 1811-1815.	1.4	17
10	Treating central nervous system lymphoma in the era of precision medicine. Expert Review of Precision Medicine and Drug Development, 2020, 5, 275-281.	0.7	1
11	Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES). Epilepsia, 2020, 61, 647-656.	5.1	28
12	Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire. Blood Advances, 2020, 4, 1357-1366.	5.2	29
13	Treatment of Primary Central Nervous System Lymphoma in Immunocompetent Patients. Current Treatment Options in Neurology, 2019, 21, 39.	1.8	2
14	Optimization of CSF biological investigations for CNS lymphoma diagnosis. American Journal of Hematology, 2019, 94, 1123-1131.	4.1	9
15	Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma. Neurology, 2019, 93, e1799-e1806.	1.1	17
16	A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study. Neuro-Oncology, 2019, 21, 1039-1048.	1.2	13
17	Pretreatment Hemoglobin as an Independent Prognostic Factor in Primary Central Nervous System Lymphomas. Oncologist, 2019, 24, e898-e904.	3.7	16
18	Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients. Haematologica, 2018, 103, e296-e299.	3.5	23

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination. <i>Seminars in Hematology</i> , 2018, 55, 179-181.	3.4	7
20	Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients. <i>Oncotarget</i> , 2018, 9, 16822-16831.	1.8	17
21	Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. <i>Journal of Neuro-Oncology</i> , 2017, 133, 315-320.	2.9	47
22	Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series. <i>Neurology</i> , 2017, 88, 101-102.	1.1	65
23	Primary Oculocerebral Lymphoma: MTX Polychemotherapy Alone on Intraocular Disease Control. <i>Ophthalmology</i> , 2016, 123, 2047-2050.	5.2	17
24	Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. <i>Neuro-Oncology</i> , 2016, 18, 1297-1303.	1.2	135
25	Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network. <i>Blood</i> , 2016, 128, 784-784.	1.4	34
26	Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e251-e259.	4.6	164
27	Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma. <i>Neurology</i> , 2015, 84, 325-326.	1.1	84
28	Very High Efficiency of ICE (Ifosfamide-Carboplatin-Etoposide) in Relapse/Refractory (R/R) Primary Central Nervous System (PCNSL) and Vitreo-Retinal (VRL) Non Hodgkin Lymphoma. a LOC Network Multicenter Retrospective Study on 58 Cases. <i>Blood</i> , 2015, 126, 1524-1524.	1.4	6